Abstract

 Lichen sclerosus vulvaris is a chronic dermatosis of inflammatory origin, which commonly affects adult, post-menopausal women. It affects the genital and perineal area, where it produces persistent itching, inflammation and pain. Over time, and if treatment is delayed, the scarring that follows the inflammation can produce significant damage such as fusion of the lips, narrowing of the introitus and abolition of the clitoris. All of this can severely affect the quality of life of these women, who are even at increased risk of vulvar cancer. To date, multiple lines of treatment have been used for this dermatosis, and there is not enough evidence to recommend one over the other. We present the case of a patient suffering from vulvar lichen sclerosus of long evolution, with little response to various treatments, who was given intravaginal Prasterone, in order to improve her sexual function, which was compromised due to the intense genital atrophy she suffered. From the beginning of the treatment the patient experienced disappearance of the symptoms associated with lichen; and in addition a notable improvement in genital trophism was observed. We wondered if Prasterone could be a good alternative for the treatment of the symptoms associated with lichen sclerosus, and if it could delay or even prevent the appearance of the trophic disorders associated with it.

Keywords: Lichen Sclerosus; Vulvar Atrophy; Prasterone; DHEA

References

1. Chi CC., et al. “Topical interventions for genital lichen sclerosus”. Cochrane Database of Systematic Reviews 12 (2011): CD008240.
2. Perqialiotis V., et al. “An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets: Treatment options for vulvar lichen sclerosus”. American Journal of Obstetrics and Gynecology (2019).
3. , et al. “Effect of intravaginal Prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy”. Journal of Sexual Medicine 12.12 (2015): 2401-2412.
4. Fernand Labrie., et al. “Is vulvovaginal atrophy due to lack of both estrogens and androgens?”. Menopause 4 (2017): 452-461.
5. Georges Pelletier., et al. “Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and intervation”. Journal of Sexual Medicine 10 (2012): 2525-2533.
6. , et al. “Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study”. Hormone Molecular Biology and Clinical Investigation 25.3 (2016): 181-190.
7. Monica A Pessina., et al. “Differential effects of Estradiol, Progesterone, and Testosterone on vaginal structural integrity”. Endocrinology1 (2006): 61-69.

Citation

Citation: Díaz Ortega Patricia and García Manero Manuel. “When the Doors are Closed, a New Window Opens: Prasterone, a New Option in the Treatment of Lichen Sclerosus? A Case Report and Discussion”. Acta Scientific Women's Health 2.6 (2020): 02-04.

Copyright

Copyright: © 2020 Díaz Ortega Patricia and García Manero Manuel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.